Status:
COMPLETED
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Renal Anemia
Eligibility:
All Genders
Brief Summary
The purpose of this study is to assess the safety and efficacy, including the incidence of thromboembolism, in renal anemia patients treated with roxadustat (EVRENZO® Tablets) in actual clinical setti...
Detailed Description
This is a post-marketing long-term specified drug use-result survey study required for products in Japan. In the survey, patient registration and data collection will be conducted using post-marketing...
Eligibility Criteria
Inclusion
- Renal anemia patients who are naïve to roxadustat.
Exclusion
- Not applicable
Key Trial Info
Start Date :
June 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 23 2025
Estimated Enrollment :
2104 Patients enrolled
Trial Details
Trial ID
NCT04408820
Start Date
June 1 2020
End Date
June 23 2025
Last Update
July 25 2025
Active Locations (47)
Enter a location and click search to find clinical trials sorted by distance.
1
Site JP00023
Aichi, Japan
2
Site JP00005
Akita, Japan
3
Site JP00002
Aomori, Japan
4
Site JP00012
Chiba, Japan